Cholangiocarcinoma Market Analysis By Treatment Type(Chemotherapy, Targeted Therapy, Immunotherapy), By Disease Indication(Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer), By Distribution Channel(Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) & Forecast 2024-2035
- PUBLISHED ON
- 28/02/2023
- NO OF PAGES
- 245
- CATEGORY
- Healthcare & Life Sciences
The rising research and development actions by pharmaceutical companies. For instance, in January 2020, Sirnaomics Inc. and Innovent Biologics, Inc. announced the collaboration for research and development using Sirnaomics’ RNAi drug candidate STP705 (cotsiranib) and Innovent’s antibody drug Tyvyt (sintilimab injection), as a combination treatment in advanced cancers such as Hepatocellular Carcinomas (HCC) and Cholangiocarcinoma (CCA). Therefore, increasing number of lead candidates in late phase clinical trial having the potential to gain regulatory approval in providing a robust opportunity for pharmaceutical manufacturers to launch novel drugs for the treatment of cholangiocarcinoma.
COVID 19 has affected many occupational sectors, and the budget of several regions deteriorated owing to the effect. Pandemic affected the economy by straight affecting the manufacturing and demand, disturbing the supply channel and having a severe financial impact on the global market. During the pandemic in June 2020, the national health institute broadcasted COVID 19 research initiatives through antibody testing. Constant growing population for cancer diagnosis through the period with have a helpful impact on the market. As the request for medical equipment augmented and people visited hospitals more than before throughout the novel coronavirus spread, the market positively impacted the virus spread.
The categories of treatment are chemotherapy and radiotherapy. The cholangiocarcinoma market Size is fragmented into 5-fluorouracil, gemcitabine, cisplatin, and others based on the sub-segment chemotherapy.
Distribution Channel Insights
On the basis of distribution channel, the cholangiocarcinoma market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies category is to observe higher adoption of cholangiocarcinoma during the forecasted period. This is mostly owing to the accessibility of experienced healthcare professionals & the safety & efficiency throughout the treatment procedures also increasing hospital administration of patients globally are the major aspects for the growth of the segment.
Region Insights
North America is governing the market, and it is anticipated that it will remain to dominate in the forecasted period. The factors the region embraces the major growth are the well-developed healthcare sector, growing number of cancer patients, and accumulating government expenditure on healthcare. In 2015, healthcare expenditure in the U.S. touched $3.2 trillion per person, 17.8% of the total GDP. The accessibility of funds for research, intensifying patient population and government support for the research and development of medication in Europe and Asia pushes the market towards growth.
Europe holds the second-largest cholangiocarcinoma market share. Owing to the continuous growth in the region like India and China, the market is experiencing high opportunities in the future. In India, the healthcare spending accounted for the fastest CAGR.
Key Companies Insights
The market for cholangiocarcinoma is moderately competitive. With the rising applications of Cholangiocarcinoma, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Cholangiocarcinoma market, ultimately boosting the market growth.
• Johnson & Johnson Private Limited
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• AstraZeneca
• GlaxoSmithKline plc
• AbbVie Inc.
• Novartis AG
• Fresenius Kabi AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Intercept Pharmaceuticals
• Kyowa Kirin Co., Ltd.
• Delcath Systems, Inc.
• Accord Healthcare
• CONMED Corporation
• Boston Scientific Corporation
• Bayer AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Other players
Some of the Recent Developments:
• In April 2020, the U.S. Food and Drug Administration had permitted the first targeted therapy for patients with cholangiocarcinoma called Pemazyre (pemigatinib). Pemazyre's sanction was founded on the outcomes of a clinical trial in which 107 patients with locally progressive or metastatic cholangiocarcinoma who had earlier received therapy and had a FGFR2 fusion or rearrangement were joined.
• In September 2019, Merck Sharp & Dohme Corp initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment bile duct cancer. The study is now in Phase 3 clinical trials and is anticipated to be completed by August 2023.
Segments
By Treatment Type
• Chemotherapy
o Gemcitabine
o Cisplatin
o Oxaliplatin
o Oxaliplatin
o 5 fluorouracil (5-FU)
• Targeted Therapy
o Pemigatinib
o Infigratinib (Phase 3)
o Ivosidenib (Phase 3)
• Immunotherapy
o Pembrolizumab (Phase 3)
• Others
By Disease Indication
• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Historic Year: 2016-2022
Forecast: 2024-2035
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI